MODESTHE – Molecular determinants of the onset of sarcopenia and osteoporosis and exploration of potential therapeutic strategies
Aging is accompanied by deregulation of trophic hormones and dysmetabolic conditions implicated in the onset of sarcopenia and osteoporosis, which are among the major contributors to frailty in old-aged patients. As growth hormone replacement therapy has often been proven to be not only useless but in some cases even harmful, there is an urgent need to study the molecular mechanisms regulating the biological functions of these hormones. In addition, nonalcoholic fatty liver disease (NAFLD), a disease characterized by excessive fat storage in the liver, frequently associated with metabolic syndrome in aging individuals, is an emerging risk factor for sarcopenia. However, the mechanisms linking NAFLD to sarcopenia are still unknown and will be investigated within this project. Finally, age-associated pathologies may also be prevented by administering active ingredients derived from plants used in traditional medicine as invigorating remedies with “anti-aging” properties, whose actual biological action on muscle and bone will be assessed.
Work packages
- WP1 Age-related hormonal dysregulation in the onset of sarcopenia and osteoporosis
- WP2 Study of the mechanisms causing sarcopenia associated with nonalcoholic fatty liver disease (NAFLD)
- WP3 Longevity from tradition
Team
Partnership
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Italy
- Department of Biological and Clinical Sciences, University of Torino, Italy
Research area: Why do we age, Age-related diseases
Principal Investigator (PI) and CO-PI:
Nicoletta Filigheddu (PI) - Researcher - Department of Translational Medicine - UPO
Claudio Molinari (Co-PI) - Associate professor - Department of Translational Medicine - UPO
AME »